Quick Comparison
| HGH Fragment 176-191 | Semaglutide | |
|---|---|---|
| Half-Life | 0.5-1 hours | 168 hours (7 days) |
| Typical Dosage | Research: 250-500 mcg subcutaneous once or twice daily, on an empty stomach. Often cycled 8-12 weeks on, 4 weeks off. The short half-life typically requires twice-daily dosing for sustained effect. | Weight management (Wegovy): 0.25 mg subcutaneous once weekly, escalating over 16 weeks to 2.4 mg once weekly. Diabetes (Ozempic): 0.25 mg subcutaneous once weekly, escalating to 1-2 mg once weekly. Oral (Rybelsus): 3 mg once daily for 30 days, then 7-14 mg once daily on an empty stomach. |
| Administration | Subcutaneous injection | Subcutaneous injection (weekly). Oral formulation available (Rybelsus). |
| Research Papers | 1 papers | 30 papers |
| Categories |
Mechanism of Action
HGH Fragment 176-191
HGH Fragment 176-191 is the unmodified C-terminal segment of human growth hormone, representing exactly the last 16 amino acids of the 191-amino-acid GH molecule. Research identified this region as containing the molecular determinants responsible for GH's lipolytic activity, independent of the N-terminal domain that binds the growth hormone receptor and drives IGF-1 production and tissue growth.
The fragment activates lipolysis in white adipose tissue through interaction with beta-adrenergic signaling pathways. This triggers the cAMP/protein kinase A cascade that phosphorylates and activates hormone-sensitive lipase and perilipin proteins on the surface of lipid droplets within fat cells. The result is the breakdown of stored triglycerides into free fatty acids and glycerol, which are released into circulation for oxidation by energy-demanding tissues such as skeletal muscle and the liver.
Because the fragment lacks the binding regions for the GH receptor (located in amino acids 1-175), it does not activate the JAK2-STAT5 signaling pathway responsible for hepatic IGF-1 synthesis, somatic growth, or the insulin-antagonistic effects of full-length growth hormone. However, the shorter half-life compared to AOD-9604 (which has an additional stabilizing tyrosine residue) means more frequent dosing is required, and clinical evidence supporting its efficacy in humans remains very limited.
Semaglutide
Semaglutide is a modified version of the natural incretin hormone GLP-1, engineered with 94% structural homology to the native peptide. It binds to GLP-1 receptors expressed throughout the body, triggering a cascade of metabolic effects. In the pancreas, it stimulates glucose-dependent insulin secretion from beta cells while suppressing glucagon release from alpha cells, providing dual glycemic control that only activates when blood sugar is elevated.
In the central nervous system, semaglutide crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamic arcuate nucleus and the brainstem's nucleus tractus solitarius. This suppresses appetite by modulating POMC/CART (anorexigenic) and NPY/AgRP (orexigenic) neuronal pathways. The result is a significant reduction in hunger, food cravings, and caloric intake — patients typically experience a fundamental shift in their relationship with food.
The extended duration of action comes from a C18 fatty di-acid chain attached at position 26 (lysine), which enables strong non-covalent binding to circulating albumin. This albumin binding shields semaglutide from DPP-4 enzymatic degradation — the process that destroys native GLP-1 within minutes — extending its half-life to approximately 7 days. Additionally, semaglutide slows gastric emptying through vagal nerve signaling, contributing to post-meal satiety and reduced glycemic excursions.
Risks & Safety
HGH Fragment 176-191
Common
injection site irritation, headache, brief dizziness.
Serious
extremely limited clinical data, no long-term safety information.
Rare
allergic reactions.
Semaglutide
Common
nausea (30-45% of users), vomiting, diarrhea, constipation, stomach pain, headache.
Serious
inflammation of the pancreas (pancreatitis), gallstones, kidney problems from dehydration, loss of muscle mass alongside fat.
Rare
thyroid tumours seen in animal studies, severe allergic reactions.
Full Profiles
HGH Fragment 176-191 →
The original, unmodified version of the growth hormone fat-burning fragment — essentially the same concept as AOD-9604 but less stable and shorter-lasting. Contains the part of growth hormone responsible for fat metabolism without the parts that cause growth or blood sugar issues. Requires more frequent dosing than AOD-9604, and has even less clinical evidence supporting its effectiveness.
Semaglutide →
The most widely prescribed weight loss medication in the world, sold as Wegovy and Ozempic. Works by dramatically reducing appetite and food cravings — most people report feeling full much faster and losing interest in snacking. In clinical trials, patients lost an average of 15-17% of their body weight. Also available as a daily pill (Rybelsus). Originally developed for type 2 diabetes, it also helps control blood sugar levels.